NEW YORK (360Dx) – BioReference Laboratories’ GenPath Oncology Diagnostics division will participate in the National Cancer Institute’s Molecular Analysis for Therapy Choice (NCI-MATCH) trial.
BioReference Labs signed a collaboration agreement with the National Cancer Institute and ECOG-ACRIN Cancer Research Group, which is coordinating the trial, BioReference parent company Opko Health announced today.
Through the collaboration, GenPath will notify the treating oncologist at one of the 1,100 participating sites when a genomic alteration is detected by GenPath’s OnkoSight that is a match to an NCI-MATCH treatment arm. The treating oncologist will evaluate other eligibility criteria and discuss with the patient the NCI-MATCH trial as a possible treatment option.
The purpose of the NCI-MATCH trial is to determine the efficacy of certain cancer therapeutics that target a patient’s genetic alterations, regardless of the cancer type.
GenPath’s OnkoSight is a proprietary product line of next-generation sequencing assays for hematologic malignancies and solid tumors focused on actionable mutations in common cancers.
“NCI-MATCH participation will allow BioReference Laboratories to offer access to a broader range of clinical trial options for our participating clients’ cancer patients,” said James Weisberger, executive vice president and chief medical officer at BioReference Laboratories. “This will help increase patient access to